Thin
1 / 2
Orforglipron is an investigational oral medication being developed by Eli Lilly for treating type 2 diabetes and obesity. It is a non-peptide GLP-1 receptor agonist, meaning it mimics the effects of a natural hormone that regulates blood sugar and appetite. Clinical trials have shown that orforglipron can lead to significant weight loss and improved blood sugar control in people with type 2 diabetes and obesity.
Orforglipron is a novel GPR40 (FFAR1) agonist, designed to enhance insulin secretion in response to elevated glucose levels. By selectively activating GPR40 receptors in pancreatic β-cells, Orforglipron improves glucose-dependent insulin release, potentially offering benefits in type 2 diabetes management. Early clinical data suggest improvements in glycemic control, HbA1c reduction, and beta-cell function, making it a promising candidate for research and development.
In original research studies, Orforglipron has been administered as an oral tablet, with doses typically ranging from 10 mg to 50 mg per day, adjusted according to clinical trial protocols and patient response. Dosage may vary in experimental studies, and all applications should follow ethical and regulatory guidelines.
Orforglipron is an investigational oral medication currently being developed by Eli Lilly for the treatment of type 2 diabetes and obesity.
It acts as a non-peptide GLP-1 receptor agonist and a novel GPR40 (FFAR1) agonist. It mimics natural hormones to regulate appetite and selectively activates receptors in pancreatic β-cells to enhance glucose-dependent insulin secretion.
Clinical trials indicate that it can lead to significant weight loss, improved blood sugar control, HbA1c reduction, and enhanced beta-cell function.
In original research studies and clinical trials, Orforglipron has been administered in the form of an oral tablet.
Doses typically range from 10 mg to 50 mg per day. The exact dosage is adjusted according to specific clinical trial protocols and individual patient response.
Orforglipron is an investigational drug being developed by Eli Lilly and Company for patients with type 2 diabetes and obesity.
